Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other (2016 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Receivables - Other of $70.0 million for Q3 2025, up 14513.78% quarter-over-quarter from $479000.0 in Q3 2021.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other (2016 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Receivables - Other history runs 5 years deep, the most recent figure standing at $70.0 million for Q3 2025.
- In Q3 2025, Receivables - Other changed N/A year-over-year to $70.0 million; the TTM figure through Sep 2025 stood at $70.0 million (changed N/A YoY), while the FY2017 annual figure was $1.1 million, up 266.67% from the prior year.
- Receivables - Other for Q3 2025 stood at $70.0 million, up from $479000.0 in the prior quarter.
- The five-year high for Receivables - Other was $70.0 million in Q3 2025, with the low at $479000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.00 Mn |
| Sep 30, 2025 | 70.00 Mn |
| Sep 30, 2021 | 479,000.00 |
| Mar 31, 2018 | 955,000.00 |
| Dec 31, 2017 | 1.10 Mn |
| Sep 30, 2017 | 1.44 Mn |
| Jun 30, 2017 | 467,200.00 |
| Dec 31, 2016 | 300,000.00 |